MA45124B1 - Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients - Google Patents

Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients

Info

Publication number
MA45124B1
MA45124B1 MA45124A MA45124A MA45124B1 MA 45124 B1 MA45124 B1 MA 45124B1 MA 45124 A MA45124 A MA 45124A MA 45124 A MA45124 A MA 45124A MA 45124 B1 MA45124 B1 MA 45124B1
Authority
MA
Morocco
Prior art keywords
treatment
antibody
biomarker
level
sample
Prior art date
Application number
MA45124A
Other languages
English (en)
French (fr)
Other versions
MA45124A (fr
Inventor
Jan Endell
Mark Winderlich
Rainer Boxhammer
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MA45124A publication Critical patent/MA45124A/fr
Publication of MA45124B1 publication Critical patent/MA45124B1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA45124A 2016-05-30 2017-05-30 Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients MA45124B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16171885 2016-05-30
PCT/EP2017/063045 WO2017207574A1 (en) 2016-05-30 2017-05-30 Methods for predicting therapeutic benefit of anti-cd19 therapy in patients

Publications (2)

Publication Number Publication Date
MA45124A MA45124A (fr) 2017-12-07
MA45124B1 true MA45124B1 (fr) 2021-05-31

Family

ID=56116221

Family Applications (2)

Application Number Title Priority Date Filing Date
MA45124A MA45124B1 (fr) 2016-05-30 2017-05-30 Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients
MA57021A MA57021B1 (fr) 2016-05-30 2017-05-30 Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA57021A MA57021B1 (fr) 2016-05-30 2017-05-30 Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients

Country Status (26)

Country Link
US (2) US20190195879A1 (https=)
EP (2) EP3916392B1 (https=)
JP (2) JP7066639B2 (https=)
KR (1) KR102416144B1 (https=)
CN (2) CN115932265B (https=)
AU (1) AU2017272608B2 (https=)
CY (1) CY1124768T1 (https=)
DK (2) DK3916392T3 (https=)
EA (1) EA201892542A1 (https=)
ES (2) ES2878156T3 (https=)
FI (1) FI3916392T3 (https=)
HR (2) HRP20240670T1 (https=)
HU (2) HUE067450T2 (https=)
IL (1) IL263103B2 (https=)
LT (2) LT3465214T (https=)
MA (2) MA45124B1 (https=)
MD (2) MD3916392T2 (https=)
MX (2) MX388502B (https=)
PL (2) PL3916392T3 (https=)
PT (2) PT3465214T (https=)
RS (2) RS62155B1 (https=)
SG (2) SG10201911958SA (https=)
SI (2) SI3465214T1 (https=)
SM (2) SMT202400204T1 (https=)
WO (1) WO2017207574A1 (https=)
ZA (2) ZA201808647B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2767063C2 (ru) 2015-08-21 2022-03-16 МорфоСис АГ Комбинации и их использование
US12358983B2 (en) 2016-10-28 2025-07-15 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
AU2020267823A1 (en) * 2019-05-03 2021-11-11 Incyte Corporation Anti-CD19 therapy in patients having a limited number of NK cells
TW202525340A (zh) * 2019-10-31 2025-07-01 美商英塞特公司 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合
KR20220104176A (ko) * 2019-10-31 2022-07-26 모르포시스 아게 순차적 항-cd19 요법
WO2021259902A1 (en) * 2020-06-22 2021-12-30 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpα-cd47 innate immune checkpoint
WO2022117799A2 (en) * 2020-12-04 2022-06-09 Morphosys Ag Anti-cd19 combination therapy
WO2026024668A1 (en) * 2024-07-22 2026-01-29 Abbott Laboratories Method of determining a volume of a liquid in a sample

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1974747E (pt) * 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
US7320991B2 (en) 2001-02-27 2008-01-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Analogs of thalidomide as potential angiogenesis inhibitors
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CA2534639C (en) 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
HUE025945T2 (en) * 2005-02-15 2016-07-28 Univ Duke Anti-CD19 antibodies and their applications in oncology
CA2611814A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
ES2365046T3 (es) 2005-12-30 2011-09-21 Merck Patent Gmbh Anticuerpos anti-cd19 con inmunogenicidad reducida.
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
RU2495882C2 (ru) 2006-09-08 2013-10-20 Медиммун, Ллк. Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
DE602007013068D1 (de) * 2006-09-13 2011-04-21 Glycode Verfahren zur untersuchung der reaktion auf eine behandlung mit einem monoklonalen antikörper
EP2176298B1 (en) 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
CN102421800A (zh) 2009-02-23 2012-04-18 格兰马克药品股份有限公司 结合cd19的人源化抗体及其用途
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
MX2013005270A (es) * 2010-11-15 2013-10-25 Medimmune Llc Terapia combinada para linfomas de limfocitos b.
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
HRP20220224T1 (hr) * 2011-08-16 2022-04-29 Morphosys Ag Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom
KR20140064873A (ko) * 2011-08-16 2014-05-28 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
WO2013090478A1 (en) * 2011-12-12 2013-06-20 Pikamab, Inc Predicting responsiveness to antibody maintenance therapy
CA2935748A1 (en) * 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
AU2015277516A1 (en) * 2014-06-16 2016-12-22 Xencor, Inc. Treatment for chronic lymphocytic leukemia (CLL)
CN107209187B (zh) * 2014-07-11 2021-04-20 国立健康与医学研究所 用于诊断血液癌症的方法

Also Published As

Publication number Publication date
MD3916392T2 (ro) 2024-10-31
IL263103B2 (en) 2023-10-01
SG11201810159TA (en) 2018-12-28
HUE067450T2 (hu) 2024-10-28
SI3916392T1 (sl) 2024-10-30
PL3465214T3 (pl) 2021-12-20
MA57021B1 (fr) 2024-05-31
EP3916392A1 (en) 2021-12-01
CY1124768T1 (el) 2022-11-25
SG10201911958SA (en) 2020-02-27
JP7511806B2 (ja) 2024-07-08
SMT202100291T1 (it) 2021-07-12
HUE054860T2 (hu) 2021-10-28
PT3465214T (pt) 2021-06-30
PL3916392T3 (pl) 2024-09-23
AU2017272608A1 (en) 2018-12-06
EP3916392B1 (en) 2024-05-01
JP2019519770A (ja) 2019-07-11
CN115932265A (zh) 2023-04-07
IL263103A (en) 2018-12-31
JP7066639B2 (ja) 2022-05-13
MA45124A (fr) 2017-12-07
CN109313194A (zh) 2019-02-05
MD3465214T2 (ro) 2021-09-30
ZA201808647B (en) 2021-05-26
WO2017207574A1 (en) 2017-12-07
FI3916392T3 (fi) 2024-06-03
MX2021014963A (es) 2022-02-24
CN109313194B (zh) 2022-11-04
ES2878156T3 (es) 2021-11-18
DK3465214T3 (da) 2021-05-31
CN115932265B (zh) 2026-04-14
RS65540B1 (sr) 2024-06-28
NZ748468A (en) 2025-05-30
HRP20240670T1 (hr) 2024-09-27
MX2018014702A (es) 2019-10-02
RS62155B1 (sr) 2021-08-31
US20220283166A1 (en) 2022-09-08
SMT202400204T1 (it) 2024-09-16
LT3916392T (lt) 2024-08-26
PT3916392T (pt) 2024-06-04
KR20190013980A (ko) 2019-02-11
JP2022119764A (ja) 2022-08-17
US20190195879A1 (en) 2019-06-27
EA201892542A1 (ru) 2019-06-28
LT3465214T (lt) 2021-10-11
BR112018074603A2 (pt) 2019-03-19
ZA202100296B (en) 2025-05-28
EP3465214A1 (en) 2019-04-10
HRP20210938T1 (hr) 2021-09-03
MX388502B (es) 2025-03-20
IL263103B1 (en) 2023-06-01
ES2981046T3 (es) 2024-10-07
CA3025823A1 (en) 2017-12-07
EP3465214B1 (en) 2021-04-28
AU2017272608B2 (en) 2023-08-10
KR102416144B1 (ko) 2022-07-04
DK3916392T3 (da) 2024-05-21
SI3465214T1 (sl) 2021-12-31

Similar Documents

Publication Publication Date Title
MA45124B1 (fr) Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients
Benguigui et al. Interferon-stimulated neutrophils as a predictor of immunotherapy response
Varettoni et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms
Holmgren et al. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate.
Sugimori et al. Origin and fate of blood cells deficient in glycosylphosphatidylinositol‐anchored protein among patients with bone marrow failure
Quartuccio et al. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study
Strasser et al. Immunological differences between colorectal cancer and normal mucosa uncover a prognostically relevant immune cell profile
De Winde et al. Tetraspanin CD37 protects against the development of B cell lymphoma
Galluzzo et al. IL12B (p40) gene polymorphisms contribute to ustekinumab response prediction in psoriasis
Lau et al. Genetic association of ankylosing spondylitis with TBX21 influences T-bet and pro-inflammatory cytokine expression in humans and SKG mice as a model of spondyloarthritis
US10725029B2 (en) Kit for in vitro or ex vivo measurement of SCD127 expression in a biological sample
Galatola et al. Gene expression profile of peripheral blood monocytes: a step towards the molecular diagnosis of celiac disease?
Shinohara et al. A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction
Worasilchai et al. Monitoring anti-Pythium insidiosum IgG antibodies and (1→ 3)-β-d-glucan in vascular pythiosis
Angelot‐Delettre et al. Intracytoplasmic detection of TCL1—but not ILT7—by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis
Nolan et al. Estimated glomerular filtration rate in sickle cell anemia is associated with polymorphisms of bone morphogenetic protein receptor 1B
Wang et al. Transcriptome analysis of gingival tissues of enamel‐renal syndrome
Dehmel et al. Chemokine receptor Ccr5 deficiency induces alternative macrophage activation and improves long‐term renal allograft outcome
Hartling et al. Gene variation in IL-7 receptor (IL-7R) α affects IL-7R response in CD4+ T cells in HIV-infected individuals
HK1211042A1 (en) Inflammation-enabling polypeptides and uses thereof
Li et al. Enhanced levels of both the membrane-bound and soluble forms of IgM Fc receptor (FcμR) in patients with chronic lymphocytic leukemia
Brown et al. Peripheral blood IFN responses to toll-like receptor 1/2 signaling associate with longer survival in men with metastatic prostate cancer treated with sipuleucel-T
Gossmann et al. A gain-of-function mutation in the Plcg2 gene protects mice from helicobacter felis-induced gastric MALT lymphoma
US10955415B2 (en) CD247 as a biomarker for assessing the effect of chemotherapeutic and biological drugs
Walker et al. The effect of systemic corticosteroid therapy on the expression of toll‐like receptor 2 and toll‐like receptor 4 in the cutaneous lesions of leprosy Type 1 reactions